Increased platelet membrane [3H]‐LSD binding in patients on chronic neuroleptic treatment
Using a [3H]‐lysergic acid diethylamide [(3H]‐LSD) binding technique, platelet 5‐hydroxytryptamine (5‐HT) receptor number and affinity were compared in schizophrenics treated with depot thioxanthenes and phenothiazines and controls. There was an approximately 30% increase in platelet receptor number...
Gespeichert in:
| Veröffentlicht in: | British journal of clinical pharmacology 1985-04, Vol.19 (4), p.453-457 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 457 |
|---|---|
| container_issue | 4 |
| container_start_page | 453 |
| container_title | British journal of clinical pharmacology |
| container_volume | 19 |
| creator | Schachter, M Geaney, DP Grahame‐Smith, DG Cowen, PJ Elliott, JM |
| description | Using a [3H]‐lysergic acid diethylamide [(3H]‐LSD) binding technique, platelet 5‐hydroxytryptamine (5‐HT) receptor number and affinity were compared in schizophrenics treated with depot thioxanthenes and phenothiazines and controls. There was an approximately 30% increase in platelet receptor number (Bmax) in the patient group. There was a decrease in affinity (increase in Kd) of about 30% in the patient group. This was probably due to the persistence of the neuroleptic in the platelet membrane preparation. There was a weak positive correlation between receptor number and total neuroleptic dosage. The increased number of 5‐HT receptors is consistent with the previously reported enhancement of 5‐HT‐induced platelet aggregation in patients treated with long‐term phenothiazines and thioxanthenes. Our findings are compatible with 5‐HT up‐regulation in human platelets produced by depot neuroleptic therapy. It is not known whether parallel changes may be occurring in brain 5‐HT receptors. |
| doi_str_mv | 10.1111/j.1365-2125.1985.tb02670.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1463802</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1562672560</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5390-87ffa85a533360f0c305bf927bc16722dab5012fe64ae283a805df2d0fb9c7353</originalsourceid><addsrcrecordid>eNqVkcuKFDEUhoMoYzv6CEIQETdV5jJJpVyMaHuZgQYFdTVISKWSmTSpVJmkdWbnI_iMPokpumh0I5hNAv93Tk7yAfAIoxqX9WxbY8pZRTBhNW4Fq3OHCG9QfX0LrA7RbbBCFPGKEYbvgnspbRHCFHN2BI6IYK1o6ApcnAcdjUqmh5NX2XiT4WCGLqpg4AU9-_Lrx8_Nx9ewc6F34RK6ACeVnQk5wTFAfRXH4DQMZhdHb6Zczrn0y0Mh7oM7VvlkHiz7Mfj89s2n9Vm1ef_ufP1yU2lGW1SJxlolmGKUUo4s0hSxzrak6TTmDSG96hjCxBp-ogwRVAnEekt6ZLtWN5TRY3C67zvtusH0ulwdlZdTdIOKN3JUTv6dBHclL8dvEp9wKhApDZ4sDeL4dWdSloNL2nhfPmHcJdlwjIlocQGf_hPEjBcPhHFU0Od7VMcxpWjsYR6M5GxRbuWsSs6q5GxRLhbldSl--OeLDqWLtpI_XnKVtPK22NIuHTBBW4rxjL3YY9-dNzf_MYB8tf4wn-hvOXG7vg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1562672560</pqid></control><display><type>article</type><title>Increased platelet membrane [3H]‐LSD binding in patients on chronic neuroleptic treatment</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Schachter, M ; Geaney, DP ; Grahame‐Smith, DG ; Cowen, PJ ; Elliott, JM</creator><creatorcontrib>Schachter, M ; Geaney, DP ; Grahame‐Smith, DG ; Cowen, PJ ; Elliott, JM</creatorcontrib><description>Using a [3H]‐lysergic acid diethylamide [(3H]‐LSD) binding technique, platelet 5‐hydroxytryptamine (5‐HT) receptor number and affinity were compared in schizophrenics treated with depot thioxanthenes and phenothiazines and controls. There was an approximately 30% increase in platelet receptor number (Bmax) in the patient group. There was a decrease in affinity (increase in Kd) of about 30% in the patient group. This was probably due to the persistence of the neuroleptic in the platelet membrane preparation. There was a weak positive correlation between receptor number and total neuroleptic dosage. The increased number of 5‐HT receptors is consistent with the previously reported enhancement of 5‐HT‐induced platelet aggregation in patients treated with long‐term phenothiazines and thioxanthenes. Our findings are compatible with 5‐HT up‐regulation in human platelets produced by depot neuroleptic therapy. It is not known whether parallel changes may be occurring in brain 5‐HT receptors.</description><identifier>ISSN: 0306-5251</identifier><identifier>EISSN: 1365-2125</identifier><identifier>DOI: 10.1111/j.1365-2125.1985.tb02670.x</identifier><identifier>PMID: 2859873</identifier><identifier>CODEN: BCPHBM</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adult ; Aging ; Antipsychotic Agents - pharmacology ; Biological and medical sciences ; Blood Platelets - metabolism ; Cell Membrane - metabolism ; Female ; Humans ; Kinetics ; Lysergic Acid Diethylamide - blood ; Lysergic Acid Diethylamide - metabolism ; Male ; Medical sciences ; Middle Aged ; Neuropharmacology ; Pharmacology. Drug treatments ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Receptors, Serotonin - metabolism ; Schizophrenia - blood ; Sex Factors ; Time Factors</subject><ispartof>British journal of clinical pharmacology, 1985-04, Vol.19 (4), p.453-457</ispartof><rights>1985 The British Pharmacological Society</rights><rights>1986 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5390-87ffa85a533360f0c305bf927bc16722dab5012fe64ae283a805df2d0fb9c7353</citedby><cites>FETCH-LOGICAL-c5390-87ffa85a533360f0c305bf927bc16722dab5012fe64ae283a805df2d0fb9c7353</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=8393113$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2859873$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schachter, M</creatorcontrib><creatorcontrib>Geaney, DP</creatorcontrib><creatorcontrib>Grahame‐Smith, DG</creatorcontrib><creatorcontrib>Cowen, PJ</creatorcontrib><creatorcontrib>Elliott, JM</creatorcontrib><title>Increased platelet membrane [3H]‐LSD binding in patients on chronic neuroleptic treatment</title><title>British journal of clinical pharmacology</title><addtitle>Br J Clin Pharmacol</addtitle><description>Using a [3H]‐lysergic acid diethylamide [(3H]‐LSD) binding technique, platelet 5‐hydroxytryptamine (5‐HT) receptor number and affinity were compared in schizophrenics treated with depot thioxanthenes and phenothiazines and controls. There was an approximately 30% increase in platelet receptor number (Bmax) in the patient group. There was a decrease in affinity (increase in Kd) of about 30% in the patient group. This was probably due to the persistence of the neuroleptic in the platelet membrane preparation. There was a weak positive correlation between receptor number and total neuroleptic dosage. The increased number of 5‐HT receptors is consistent with the previously reported enhancement of 5‐HT‐induced platelet aggregation in patients treated with long‐term phenothiazines and thioxanthenes. Our findings are compatible with 5‐HT up‐regulation in human platelets produced by depot neuroleptic therapy. It is not known whether parallel changes may be occurring in brain 5‐HT receptors.</description><subject>Adult</subject><subject>Aging</subject><subject>Antipsychotic Agents - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Blood Platelets - metabolism</subject><subject>Cell Membrane - metabolism</subject><subject>Female</subject><subject>Humans</subject><subject>Kinetics</subject><subject>Lysergic Acid Diethylamide - blood</subject><subject>Lysergic Acid Diethylamide - metabolism</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Receptors, Serotonin - metabolism</subject><subject>Schizophrenia - blood</subject><subject>Sex Factors</subject><subject>Time Factors</subject><issn>0306-5251</issn><issn>1365-2125</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1985</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkcuKFDEUhoMoYzv6CEIQETdV5jJJpVyMaHuZgQYFdTVISKWSmTSpVJmkdWbnI_iMPokpumh0I5hNAv93Tk7yAfAIoxqX9WxbY8pZRTBhNW4Fq3OHCG9QfX0LrA7RbbBCFPGKEYbvgnspbRHCFHN2BI6IYK1o6ApcnAcdjUqmh5NX2XiT4WCGLqpg4AU9-_Lrx8_Nx9ewc6F34RK6ACeVnQk5wTFAfRXH4DQMZhdHb6Zczrn0y0Mh7oM7VvlkHiz7Mfj89s2n9Vm1ef_ufP1yU2lGW1SJxlolmGKUUo4s0hSxzrak6TTmDSG96hjCxBp-ogwRVAnEekt6ZLtWN5TRY3C67zvtusH0ulwdlZdTdIOKN3JUTv6dBHclL8dvEp9wKhApDZ4sDeL4dWdSloNL2nhfPmHcJdlwjIlocQGf_hPEjBcPhHFU0Od7VMcxpWjsYR6M5GxRbuWsSs6q5GxRLhbldSl--OeLDqWLtpI_XnKVtPK22NIuHTBBW4rxjL3YY9-dNzf_MYB8tf4wn-hvOXG7vg</recordid><startdate>198504</startdate><enddate>198504</enddate><creator>Schachter, M</creator><creator>Geaney, DP</creator><creator>Grahame‐Smith, DG</creator><creator>Cowen, PJ</creator><creator>Elliott, JM</creator><general>Blackwell Publishing Ltd</general><general>Blackwell Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>198504</creationdate><title>Increased platelet membrane [3H]‐LSD binding in patients on chronic neuroleptic treatment</title><author>Schachter, M ; Geaney, DP ; Grahame‐Smith, DG ; Cowen, PJ ; Elliott, JM</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5390-87ffa85a533360f0c305bf927bc16722dab5012fe64ae283a805df2d0fb9c7353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1985</creationdate><topic>Adult</topic><topic>Aging</topic><topic>Antipsychotic Agents - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Blood Platelets - metabolism</topic><topic>Cell Membrane - metabolism</topic><topic>Female</topic><topic>Humans</topic><topic>Kinetics</topic><topic>Lysergic Acid Diethylamide - blood</topic><topic>Lysergic Acid Diethylamide - metabolism</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Receptors, Serotonin - metabolism</topic><topic>Schizophrenia - blood</topic><topic>Sex Factors</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schachter, M</creatorcontrib><creatorcontrib>Geaney, DP</creatorcontrib><creatorcontrib>Grahame‐Smith, DG</creatorcontrib><creatorcontrib>Cowen, PJ</creatorcontrib><creatorcontrib>Elliott, JM</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schachter, M</au><au>Geaney, DP</au><au>Grahame‐Smith, DG</au><au>Cowen, PJ</au><au>Elliott, JM</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Increased platelet membrane [3H]‐LSD binding in patients on chronic neuroleptic treatment</atitle><jtitle>British journal of clinical pharmacology</jtitle><addtitle>Br J Clin Pharmacol</addtitle><date>1985-04</date><risdate>1985</risdate><volume>19</volume><issue>4</issue><spage>453</spage><epage>457</epage><pages>453-457</pages><issn>0306-5251</issn><eissn>1365-2125</eissn><coden>BCPHBM</coden><abstract>Using a [3H]‐lysergic acid diethylamide [(3H]‐LSD) binding technique, platelet 5‐hydroxytryptamine (5‐HT) receptor number and affinity were compared in schizophrenics treated with depot thioxanthenes and phenothiazines and controls. There was an approximately 30% increase in platelet receptor number (Bmax) in the patient group. There was a decrease in affinity (increase in Kd) of about 30% in the patient group. This was probably due to the persistence of the neuroleptic in the platelet membrane preparation. There was a weak positive correlation between receptor number and total neuroleptic dosage. The increased number of 5‐HT receptors is consistent with the previously reported enhancement of 5‐HT‐induced platelet aggregation in patients treated with long‐term phenothiazines and thioxanthenes. Our findings are compatible with 5‐HT up‐regulation in human platelets produced by depot neuroleptic therapy. It is not known whether parallel changes may be occurring in brain 5‐HT receptors.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>2859873</pmid><doi>10.1111/j.1365-2125.1985.tb02670.x</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0306-5251 |
| ispartof | British journal of clinical pharmacology, 1985-04, Vol.19 (4), p.453-457 |
| issn | 0306-5251 1365-2125 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1463802 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adult Aging Antipsychotic Agents - pharmacology Biological and medical sciences Blood Platelets - metabolism Cell Membrane - metabolism Female Humans Kinetics Lysergic Acid Diethylamide - blood Lysergic Acid Diethylamide - metabolism Male Medical sciences Middle Aged Neuropharmacology Pharmacology. Drug treatments Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopharmacology Receptors, Serotonin - metabolism Schizophrenia - blood Sex Factors Time Factors |
| title | Increased platelet membrane [3H]‐LSD binding in patients on chronic neuroleptic treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T11%3A37%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Increased%20platelet%20membrane%20%5B3H%5D%E2%80%90LSD%20binding%20in%20patients%20on%20chronic%20neuroleptic%20treatment&rft.jtitle=British%20journal%20of%20clinical%20pharmacology&rft.au=Schachter,%20M&rft.date=1985-04&rft.volume=19&rft.issue=4&rft.spage=453&rft.epage=457&rft.pages=453-457&rft.issn=0306-5251&rft.eissn=1365-2125&rft.coden=BCPHBM&rft_id=info:doi/10.1111/j.1365-2125.1985.tb02670.x&rft_dat=%3Cproquest_pubme%3E1562672560%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1562672560&rft_id=info:pmid/2859873&rfr_iscdi=true |